OpenAI CEO Sam Altman developing brain tech to rival Neuralink

Altman enters brain tech

Sam Altman, the CEO of OpenAI, is co-founding a new company called Merge Labs that aims to develop advanced brain-computer interfaces. The project signals a major shift from software to hardware and neurotech.

Reporters say the move positions Altman’s Merge Labs as a competitor to Elon Musk’s Neuralink, setting up a rivalry between an implant-based approach and reported non-invasive research.

Merge Labs versus Neuralink

Early reporting frames Merge Labs as a potential rival to Neuralink, which uses implanted electrodes, while Merge Labs is reported to be exploring non-invasive approaches (for example, ultrasound or magnetic modulation combined with biomolecular methods).

These accounts are based on news reporting and anonymous sources; the approaches remain experimental. The stakes are high: human cognition merging with machines may redefine future tech.

Non-invasive interface ambition

Several reports indicate Merge Labs is aiming for a non-invasive BCI that would avoid open-skull implants; reporting suggests the team is exploring sound-wave (ultrasound) or magnetic approaches to detect or modulate neural activity, but details about any working device or method have not been publicly validated.

If the technology proves reliable and safe, a non-invasive approach could broaden the pool of potential users and change the regulatory path compared with implantable devices, but it would still face rigorous clinical and regulatory review.

Altman may have chosen this path to sidestep some of Neuralink’s legacy issues. Non-invasive BCI represents a major technological leap.

Technical team and expertise

Reporting names Caltech biomolecular engineer Mikhail Shapiro as a key technical hire. Shapiro’s published work on non-invasive neural imaging and biomolecular interfaces has been cited as the technical basis for the strategy reported by outlets.

That hire is a signal of serious R&D ambitions if confirmed. Having a top scientist gives the venture legitimacy and signals depth of ambition.

It’s not just a passive investment: the team is being assembled to compete. Expect rigorous R&D in the coming years.

Scale of funding and valuation

News reports say Merge Labs is seeking roughly $250 million in funding at about an $850 million valuation and that investment talks involve OpenAI’s backers; neither Merge Labs nor OpenAI has issued a public confirmation at the time of reporting.

Brain-computer interfaces are seen as the next frontier in human-machine interaction. For Altman, it’s a strategic bet on long-term leadership.

Strategic vision

Altman has previously discussed the idea of closer human–machine integration in public remarks and filings; reporters say Merge Labs appears to reflect that long-standing interest in ‘human-AI’ integration rather than being a sudden pivot.

There’s also a philosophical layer: how humans evolve with intelligent machines. Merge Labs may define a new trajectory for human-computer symbiosis.

Potential applications and use-cases

The technology could enable thought-driven control of devices, communication for paralyzed individuals, faster productivity tools, or entirely new interfaces. It might reshape accessibility, gaming, augmented reality, or brain-based computing.

Because it’s non-invasive, the startup could aim for consumer as well as medical markets. The scope is vast. But realisation will take years of testing and regulatory work.

Competitive landscape and timing

Neuralink, along with other neurotech firms, has already made headlines for implants and initial trials. Merge Labs comes into a crowded but evolving field. Non-invasive BCI may lead the next wave.

But success depends on hardware, signal fidelity, safety, and regulation. Timing is critical: whoever cracks the interface first may capture massive market share. Tensions in the neurotech ecosystem will continue to escalate.

Ethical and safety considerations

Brain-computer interfaces raise profound ethical questions: privacy of thoughts, control of devices, unintended consequences, data security, and psychological effects.

Altman, known for caution around AI risk, must now navigate neuro-risk. Non-invasive devices may mitigate some surgical risks but introduce new ones (misinterpretation, surveillance). Ethical frameworks will be central to public acceptance.

Regulatory and clinical hurdles

Medical devices face stringent regulation (FDA, CE, etc.). Neurotech adds complexity because of the human brain’s impact. Clinical trials, long-term safety, and accuracy are prerequisites.

Merge Labs must prove reliability and safety to enter consumer markets. Non-invasive promise helps but doesn’t remove oversight. The road from lab to product will be long.

Business models and monetisation

Revenue streams may include medical applications (such as assistive devices), consumer brain-interface peripherals, licensing technology to manufacturers, or subscription models. Altman’s backing suggests he aims for scale, not just a niche.

The hardware + software stack could monetise brain-AI integration in new ways. Integration with OpenAI’s ecosystem may offer synergies. Business models will evolve as the tech matures.

Implications for OpenAI

For OpenAI, the move signals diversification into hardware and neurotechnology. It extends the AI stack from software into human interface layers.

It also means deeper integration of AI across human experience. But it also raises questions: are resources being stretched? Does this shift focus from core AI models? The venture could transform OpenAI’s strategic trajectory.

Impact on society and workforce

If brain-computer interfaces become mainstream, how we work, learn, and interact may change. Tasks might become more cognitive-driven, devices responsive to thoughts, and accessibility redefined.

Workforce skill sets may shift toward brain-machine design. There may also be sociological impacts (inequality, brain access). The societal ripple effects are enormous.

Risks for the neurotech race

High development costs, long timeframes, safety setbacks, regulatory delays, consumer pushback, and technological bottlenecks pose significant risks.

If Merge Labs fails to deliver, the market may remain niche for years. Investors will watch closely. For Altman, failure could affect reputation. The race is high stakes, and pitfalls abound.

What to watch next?

Watch for official announcements from Merge Labs, funding rounds, prototype reveals, clinical trial starts, partnerships with academic or medical institutions, and regulatory approvals.

Also, keep an eye on Neuralink’s responses, competitor advances, and media narratives about the human-AI merger. Technology watchers should monitor how fast this venture progresses.

The secret brain of OnePlus 13 revealed. Meet Plus Mind, the brain behind OnePlus 13.

Call to action

Sam Altman’s entry into brain-computer interface tech marks a major development in neurotechnology and AI convergence. Merge Labs aims to challenge Neuralink with a non-invasive approach, backed by top talent and serious funding.

Whether you’re an investor, developer, researcher, or tech follower, this is one to watch. Consider what human-machine integration will mean for your work and life. Stay informed.

China’s latest move could redefine the brain-computer world. Explore how China sets a new standard to lead the brain-computer race.

Do you believe non-invasive brain-computer interfaces from Merge Labs will succeed sooner than implant-based systems, and are you comfortable with thinking-driven devices in everyday life? Tell us in the comments.

Read More From This Brand:

• Elon Musk’s brain chips will soon be tested on volunteers in the UK
• China is rapidly developing a brain-computer interface industry
• Sam Altman flags privacy risks in ChatGPT therapy

Don’t forget to follow us for more exclusive content right here on MSN.

If you like this story, you’ll LOVE our Free email newsletter. Join today and be the first to receive stories like these.

This slideshow was made with AI assistance and human editing.